224 related articles for article (PubMed ID: 15487449)
1. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
[TBL] [Abstract][Full Text] [Related]
2. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
3. [Thyroid papillary cancer using TPO staining].
Nygaard B; Frisch T; Kiss K
Ugeskr Laeger; 2008 Apr; 170(18):1571. PubMed ID: 18454932
[TBL] [Abstract][Full Text] [Related]
4. [CD26/dipeptidyl peptidase IV and thyroid peroxidase as molecular markers for differentiated thyroid carcinoma].
Umeki K; Yamamoto I; Maruta J; Aratake Y; Ono I; Uemura Y; Tanaka T; Toyoda K; Kotani T; Noguchi S; Sakamoto F; Konoe K; Ohtaki S
Rinsho Byori; 1996 Jan; 44(1):42-50. PubMed ID: 8691639
[TBL] [Abstract][Full Text] [Related]
5. Follicular thyroid lesions, elements that affect both diagnosis and prognosis.
Zeiger MA; Dackiw AP
J Surg Oncol; 2005 Mar; 89(3):108-13. PubMed ID: 15719377
[TBL] [Abstract][Full Text] [Related]
6. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.
Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G
J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
8. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical loss of thyroid peroxidase in papillary thyroid carcinoma: strong suppression of peroxidase gene expression.
Tanaka T; Umeki K; Yamamoto I; Sugiyama S; Noguchi S; Ohtaki S
J Pathol; 1996 May; 179(1):89-94. PubMed ID: 8691351
[TBL] [Abstract][Full Text] [Related]
11. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 immunodetection may improve cytological diagnosis of occult papillary thyroid carcinoma.
Pisani T; Vecchione A; Giovagnolii MR
Anticancer Res; 2004; 24(2C):1111-2. PubMed ID: 15154632
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic role of markers dipeptidyl peptidase IV and thyroid peroxidase in thyroid tumors.
Kholová I; Ludvíkova M; Ryska A; Topolcan O; Pikner R; Pecen L; Cáp J; Holubec L
Anticancer Res; 2003; 23(2A):871-5. PubMed ID: 12820316
[TBL] [Abstract][Full Text] [Related]
14. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
15. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies.
Inohara H; Segawa T; Miyauchi A; Yoshii T; Nakahara S; Raz A; Maeda M; Miyoshi E; Kinoshita N; Yoshida H; Furukawa M; Takenaka Y; Takamura Y; Ito Y; Taniguchi N
Biochem Biophys Res Commun; 2008 Nov; 376(3):605-10. PubMed ID: 18809382
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 is not useful in thyroid FNA.
Mills LJ; Poller DN; Yiangou C
Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608
[TBL] [Abstract][Full Text] [Related]
18. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
19. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
